Principal causes of death in the placebo group were staphylococcal infections, gastrointestinal hemorrhage, intestinal perforation, multiorgan failure, pneumonia, sepsis , and disease progression . Overall, nonhematologic adverse occasions occurred at an identical rate in the two groups. Occasions that occurred more in the ruxolitinib group were ecchymosis frequently, dizziness, and headache . The most typical grade three or four 4 nonhematologic adverse events happened more frequently in the placebo group. Anemia and thrombocytopenia were the most frequent hematologic adverse events and a reason for treatment discontinuation in one patient in each study-drug group for each event. About half of all grade three or four 4 adverse events of anemia in the ruxolitinib group happened during the first 8 weeks of therapy.Related StoriesInnovative single-use torque instruments utilize hard polycarbonate from BayerGreater evidence-based help necessary for depressed workers – New report from The Work FoundationWHO committed to helping Nepal deliver health care to its residents, says WHO South-East Asia Regional DirectorStudy individuals were of different age groups in various states of health, who were electively seeking medical treatment or evaluation and who were considered competent to create their own medical decisions. Of the patients interviewed, over 90 % supported the idea of asking sufferers to designate a proxy for health care on a routine basis.